With drug price reform at a fever pitch and the 2020 election fast approaching, D.C. is buzzing with flashy proposals to confront pharma.
All of them face big hurdles, though—not least of which is pharma's lobbying prowess. Could a new Senate bill get over the hump?
Two chief members of the Senate Finance Committee—Chairman Chuck Grassley and ranking Democrat Ron Wyden—certainly hope so. They unfurled a bipartisan bill Tuesday aimed at lowering drug prices through a combination of Medicare Part B and D changes and rebates forced on brand-name drugmakers.
Print Page
Email to a Friend